<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319712455216</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319712455216</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Diabetes</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neutrophil–Lymphocyte Ratio as a Predictor of Major Adverse Cardiac Events Among Diabetic Population</article-title>
<subtitle>A 4-Year Follow-Up Study</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Azab</surname>
<given-names>Basem</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712455216">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319712455216"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chainani</surname>
<given-names>Vinod</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319712455216">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shah</surname>
<given-names>Neeraj</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319712455216">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McGinn</surname>
<given-names>Joseph T.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712455216">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319712455216">
<label>1</label>Department of Surgery, Staten Island University Hospital, Staten Island, NY, USA</aff>
<aff id="aff2-0003319712455216">
<label>2</label>Department of Internal Medicine, Staten Island University Hospital, Staten Island, NY, USA</aff>
<author-notes>
<corresp id="corresp1-0003319712455216">Basem Azab, Department of Surgery, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY, 10305, USA. Email: <email>basemnady2000@yahoo.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>6</issue>
<fpage>456</fpage>
<lpage>465</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The neutrophil–lymphocyte ratio (NLR) is an inflammatory marker of major adverse cardiac events (MACEs) in both acute coronary syndromes and stable coronary artery disease. The use of NLR as a predictive tool for MACEs among diabetic patients has not been elucidated. An observational study included 338 diabetic patients followed at our clinic between 2007 and 2011. Patients were arranged into equal tertiles according to the 2007 NLR. The MACEs included acute myocardial infarction, coronary revascularization, and mortality. The lowest NLR tertile (NLR &lt;1.6) had fewer MACEs compared with the highest NLR tertile (NLR &gt;2.36; MACEs were 6 of 113 patients vs 24 of 112 patients, respectively; <italic>P</italic> &lt; .0001). In a multivariate model, the adjusted hazard ratio of third NLR tertile compared with first NLR tertile was 2.8 (95% confidence interval 1.12-6.98, <italic>P</italic> = .027). The NLR is a significant independent predictor of MACEs in diabetic patients. Further studies with larger numbers are needed.</p>
</abstract>
<kwd-group>
<kwd>neutrophil–lymphocyte ratio</kwd>
<kwd>NLR</kwd>
<kwd>diabetes</kwd>
<kwd>major adverse cardiac events and MACEs</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319712455216">
<title>Introduction</title>
<p>Diabetes mellitus (DM) is a ubiquitous disease that affects a large number of people (8.3% of US population in 2011 and 6.6% of world population in 2010).<sup>
<xref ref-type="bibr" rid="bibr1-0003319712455216">1</xref>
</sup> Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with DM.<sup>
<xref ref-type="bibr" rid="bibr2-0003319712455216">2</xref>
</sup> According to the Framingham Study, the presence of DM doubled the age-adjusted risk of CVD in men and tripled it in women.<sup>
<xref ref-type="bibr" rid="bibr3-0003319712455216">3</xref>
</sup> The Multiple Risk Factor Intervention Trial (MRFIT) also supports the understanding that DM is a major risk factor for major adverse CVD events.<sup>
<xref ref-type="bibr" rid="bibr4-0003319712455216">4</xref>
</sup> These major adverse cardiovascular events (MACEs) include acute myocardial infarction (AMI), revascularization, and cardiovascular death. Currently, many of the markers for MACEs in diabetic patients are the same as those used to assess risk in the general, nondiabetic population. Additionally, there are markers that are exclusive to diabetic patients (eg, microalbuminuria, elevated serum B<sub>2</sub>-microglobulin, glycated hemoglobin [HbA<sub>1c</sub>], fasting glucose, and Von Willebrand factor), which represent an increased risk of MACEs in this population.<sup>
<xref ref-type="bibr" rid="bibr5-0003319712455216">5</xref>
</sup>
</p>
<p>Libby et al described the link between various inflammatory conditions (eg, hypertension, smoking, obesity, and DM) and atherosclerosis.<sup>
<xref ref-type="bibr" rid="bibr6-0003319712455216">6</xref>
</sup> As a proinflammatory condition, DM was attributed to the production of advanced gylcation end products and oxygen free radicals.<sup>
<xref ref-type="bibr" rid="bibr7-0003319712455216">7</xref>,<xref ref-type="bibr" rid="bibr8-0003319712455216">8</xref>
</sup> The neutrophil–lymphocyte ratio (NLR) as an inflammatory marker was proved to be a significant independent predictor of adverse outcomes in patients with acute coronary syndrome<sup>
<xref ref-type="bibr" rid="bibr9-0003319712455216">9</xref>
<xref ref-type="bibr" rid="bibr10-0003319712455216"/>
<xref ref-type="bibr" rid="bibr11-0003319712455216"/>
<xref ref-type="bibr" rid="bibr12-0003319712455216"/>–<xref ref-type="bibr" rid="bibr13-0003319712455216">13</xref>
</sup> as well as those with stable coronary artery disease (CAD).<sup>
<xref ref-type="bibr" rid="bibr14-0003319712455216">14</xref>
</sup> The aim of our study was to evaluate NLR as a predictor of MACEs in diabetic patients.</p>
</sec>
<sec id="section2-0003319712455216" sec-type="methods">
<title>Methods</title>
<p>This is a retrospective longitudinal cohort study comprising 338 consecutive patients with type 2 DM presenting at the outpatient department of Staten Island University Hospital (SIUH) from 2007 to 2011. Staten Island has a population of 491 730 (2009 census bureau estimates, http://quickfacts.census.gov/qfd/states/36/36085.html) and consists of a predominantly white population (76%, with 64% non-Hispanic white), mainly Italian Americans. The SIUH is the largest hospital and the only tertiary care angioplasty-providing center on the island. Inclusion criteria were patients with type 2 DM with at least 1 documented fasting plasma glucose level of <underline>≥</underline>126 mg/dL or HbA<sub>1c</sub> <underline>≥</underline>7%, and being treated with diet intervention and/or oral hypoglycemics and/or insulin. Exclusion criteria were patients who had already experienced a major cardiovascular event (AMI, percutaneous coronary intervention [PCI], or coronary artery bypass grafting [CABG]) before the start of the study in 2007. The end point, that is, MACEs was defined as the occurrence of AMI, PCI, CABG, or cardiac-related death. Data collection was accomplished through electronic chart review. Information on laboratory parameters like white blood cell (WBC) count with differential, absolute number of neutrophils, lymphocytes, and monocytes, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), serum creatinine, estimated glomerular filtration rate (eGFR) (according to the Modification of Diet in Renal Disease [MDRD] equation using serum creatinine, age, race, and gender), hemoglobin, HbA<sub>1c</sub>, and albuminuria was collected from the date nearest to the first clinical encounter in 2007. Differential leukocyte counts were obtained by the Coulter Counter technique (Coulter Gen-S Hematology Analyzer, Beckman Coulter Corp, Hialeah, Florida). Data on the end-points (AMI, PCI, CABG, and mortality) were collected from the electronic medical records and social security death index.</p>
<p>The patients were categorized into 3 equal tertiles according to their baseline 33rd and 66th NLR percentiles. The tertiles obtained from our data were NLR &lt;1.6, 1.6 ≤ NLR ≤ 2.4, and NLR &gt; 2.4. Continuous variables were presented as mean ± standard deviation (SD), and categorical variables were presented as frequencies and percentages. For group comparisons, chi-square and Fisher exact tests were used for categorical variables and analysis of variance (ANOVA) and Kruskal-Wallis tests were used for continuous variables (depending upon the distribution of the continuous variable). Statistical analysis was performed using STATA version 11.0. Kaplan-Meier survival curves were plotted to illustrate the difference in the 4-year MACE rate in the different NLR tertiles. These curves were compared using log rank tests. Cox proportional hazards model was used to build a multivariate model in order to evaluate the independent effect of NLR on MACEs. Initially, exploratory univariate analysis was performed to identify the variables associated with MACEs. In the final model, variables with a univariate <italic>P</italic> &lt; .2 and those thought to be clinically significant were included. The following variables were incorporated in the final multivariate model to adjust for any potential confounding factors age, sex, hypertension, CAD, congestive heart failure (CHF), smoking, glycemic control, hyperlipidemia, and obesity. Thus, sex, glycemic control (defined as HbA<sub>1c</sub> ≤6.5 %), hyperlipidemia, and obesity were incorporated in the final model (despite their univariate <italic>P</italic> &gt; .2) because they were judged to be clinically significant confounders in the relationship between NLR and MACEs. Backward elimination was performed in order to build the final model by stepwise elimination of variables with <italic>P</italic> &gt; .05, starting with variables having the largest <italic>P</italic> value. Violations of the constant hazard assumption were evaluated using interaction between covariate and time and log-log survival plots, for both the initial and the final models. Goodness of fit of the final model with the data was assessed by graphing the Nelson-Aalen cumulative hazard against the Cox-Snell residuals, which showed that the hazard function closely followed the 45° line; thus, overall the final model fit the data very well. Subsequently, superiority of NLR over other leucocyte parameters was evaluated by building multivariate cox models containing other leucocyte parameters and the same confounding variables except NLR.</p>
</sec>
<sec id="section3-0003319712455216">
<title>Results</title>
<p>
<xref ref-type="table" rid="table1-0003319712455216">Table 1</xref> shows the baseline characteristics of our population of 338 diabetic patients. Median age was 58 years, with 36% males, 64% females, and predominantly white ethnicity (38.5%). <xref ref-type="table" rid="table1-0003319712455216">Table 1</xref> also shows the variability in the baseline characteristics in the 3 NLR tertile groups. We see that patients in the higher NLR tertile tended to be older, white, and have a higher proportion of CVD risk factors like obesity, CHF, CAD, albuminuria, low eGFR, and high serum creatinine levels.</p>
<table-wrap id="table1-0003319712455216" position="float">
<label>Table 1.</label>
<caption>
<p>Characteristics of 338 Type 2 Diabetes Mellitus Patients by NLR Tertile.</p>
</caption>
<graphic alternate-form-of="table1-0003319712455216" xlink:href="10.1177_0003319712455216-table1.tif"/>
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall (n = 338)</th>
<th>NLR Tertile 1 (NLR &lt; 1.6) (n = 113)</th>
<th>NLR Tertile 2 (1.6 <underline>&lt; </underline>NLR <underline>&lt; </underline>2.4) (n = 113)</th>
<th>NLR Tertile 3 (NLR &gt; 2.4) (n = 114)</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline characteristics</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td> </td>
</tr>
<tr>
<td> Age in years</td>
<td>58.1 <underline>±</underline> 0.6</td>
<td>56.1 <underline>±</underline> 1.1 </td>
<td>60 <underline>±</underline> 1.1</td>
<td>58.3 <underline>±</underline> 1.0</td>
<td>
<italic>.03</italic> </td>
</tr>
<tr>
<td> Male</td>
<td>122 (36.1%)</td>
<td>35 (31%)</td>
<td>39 (34.5%)</td>
<td>48 (42.9%)</td>
<td>.16</td>
</tr>
<tr>
<td> Caucasian race</td>
<td>130 (38.5%)</td>
<td>26 (23%)</td>
<td>48 (42.5%)</td>
<td>56 (50%)</td>
<td>
<italic>&lt;.001</italic>
</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Hypertension</td>
<td>261 (77.2%)</td>
<td>90 (79.6%)</td>
<td>90 (79.6%)</td>
<td>81 (72.3%)</td>
<td>.319</td>
</tr>
<tr>
<td> Dyslipidemia</td>
<td>261 (77.2%)</td>
<td>89 (78.8%)</td>
<td>84 (74.3%)</td>
<td>88 (78.6%)</td>
<td>.669</td>
</tr>
<tr>
<td> Obesity</td>
<td>216 (63.9%)</td>
<td>66 (58.4%)</td>
<td>66 (58.4%)</td>
<td>84 (75%)</td>
<td>
<italic>.011</italic>
</td>
</tr>
<tr>
<td> Congestive heart failure</td>
<td>22 (6.5%)</td>
<td>2 (1.8%)</td>
<td>9 (7.9%)</td>
<td>11 (9.8%)</td>
<td>
<italic>.037</italic>
</td>
</tr>
<tr>
<td> Cerebrovascular event</td>
<td>15 (4.4%)</td>
<td>3 (2.7%)</td>
<td>9 (8%)</td>
<td>3 (2.7%)</td>
<td>.114</td>
</tr>
<tr>
<td> Coronary artery disease</td>
<td>77 (22.8%)</td>
<td>11 (9.7%)</td>
<td>37 (32.7%)</td>
<td>29 (25.9%)</td>
<td>
<italic>&lt;.001</italic> </td>
</tr>
<tr>
<td> Smoking</td>
<td>98 (29%)</td>
<td>29 (25.7%)</td>
<td>38 (33.6%)</td>
<td>31 (27.7%)</td>
<td>.39</td>
</tr>
<tr>
<td>Diabetes complications</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Neuropathy</td>
<td>83 (24.6%)</td>
<td>26 (23%)</td>
<td>24 (21.2%)</td>
<td>33 (29.5%)</td>
<td>.321</td>
</tr>
<tr>
<td> Retinopathy</td>
<td>35 (10.4%)</td>
<td>13 (11.5%)</td>
<td>11 (9.7%)</td>
<td>11 (9.8%)</td>
<td>.886</td>
</tr>
<tr>
<td>Albuminuria<sup>a</sup>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> None</td>
<td>207 (64.3%)</td>
<td>78 (73.6%)</td>
<td>66 (61.1%)</td>
<td>63 (58.3%)</td>
<td>
<italic>.032</italic>
</td>
</tr>
<tr>
<td> Microalbuminuria</td>
<td>79 (24.5%)</td>
<td>22 (20.7%)</td>
<td>31 (28.7%)</td>
<td>26 (24.1%)</td>
<td>
</td>
</tr>
<tr>
<td> Macroalbuminuria</td>
<td>36 (11.2%)</td>
<td>6 (5.7%)</td>
<td>11 (10.2%)</td>
<td>19 (17.6%)</td>
<td>
</td>
</tr>
<tr>
<td> Low eGFR (&lt;60 ml/m<sup>2</sup>)</td>
<td>75 (22.2%)</td>
<td>12 (10.6%)</td>
<td>36 (31.9%)</td>
<td>27 (24.1%)</td>
<td>
<italic>.001</italic>
</td>
</tr>
<tr>
<td> Diabetic foot ulcer</td>
<td>49 (14.5%)</td>
<td>15 (13.3%)</td>
<td>12 (10.6%)</td>
<td>22 (19.6%)</td>
<td>.142</td>
</tr>
<tr>
<td>Glycemic control</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> HbA<sub>1c</sub> &gt; 6.5%</td>
<td>249 (73.7%)</td>
<td>85 (75.2%)</td>
<td>79 (69.9%)</td>
<td>85 (75.9%)</td>
<td>.536</td>
</tr>
<tr>
<td>Laboratory parameters</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Serum creatinine (mg/dl)</td>
<td>0.98 <underline>±</underline> 0.02</td>
<td>0.92 <underline>±</underline> 0.03</td>
<td>1.04 <underline>±</underline> 0.04</td>
<td>0.99 <underline>±</underline> 0.03</td>
<td>
<italic>.024</italic>
</td>
</tr>
<tr>
<td> Hemoglobin (g/dl)</td>
<td>12.9 <underline>±</underline> 0.1</td>
<td>13.0 <underline>±</underline> 0.1</td>
<td>12.8 <underline>±</underline> 0.2</td>
<td>12.8 <underline>±</underline> 0.2</td>
<td>.51</td>
</tr>
<tr>
<td> HDL-C</td>
<td>42.1 <underline>±</underline> 0.8</td>
<td>43.1 <underline>±</underline> 1.4</td>
<td>42.6 <underline>±</underline> 1.5</td>
<td>40.6 <underline>±</underline> 1.3</td>
<td>.261</td>
</tr>
<tr>
<td> LDL-C</td>
<td>100.9 <underline>±</underline> 2.1</td>
<td>105.3 <underline>±</underline> 3.8</td>
<td>102.1 <underline>±</underline> 3.6</td>
<td>95.1 <underline>±</underline> 3.2</td>
<td>.141</td>
</tr>
<tr>
<td> WBC count (×10<sup>3</sup>/μL)</td>
<td>7.3 <underline>±</underline> 0.1</td>
<td>6.6 <underline>±</underline> 0.2</td>
<td>7.2 <underline>±</underline> 0.2</td>
<td>8.0 <underline>±</underline> 0.2</td>
<td>&lt;.001 </td>
</tr>
<tr>
<td> Neutrophil count (×10<sup>3</sup>/μL)</td>
<td>4.3 <underline>±</underline> 0.1</td>
<td>3.2 <underline>± </underline>0.1</td>
<td>4.3 <underline>±</underline> 0.1</td>
<td>5.5 <underline>±</underline> 0.1</td>
<td>
<italic>.0001</italic>
</td>
</tr>
<tr>
<td> Lymphocyte count (×10<sup>3</sup>/μL)</td>
<td>2.2 <underline>±</underline> 0.04</td>
<td>2.7 <underline>±</underline> 0.08</td>
<td>2.14 <underline>±</underline> 0.05</td>
<td>1.7 <underline>±</underline> 0.05</td>
<td>
<italic>.0001</italic>
</td>
</tr>
<tr>
<td> Monocyte count (×10<sup>3</sup>/μL)</td>
<td>0.51 <underline>±</underline> 0.01</td>
<td>0.48 <underline>±</underline> 0.02</td>
<td>0.52 <underline>±</underline> 0.02</td>
<td>0.54 <underline>±</underline> 0.02</td>
<td>
<italic>.01</italic>
</td>
</tr>
<tr>
<td>Adverse outcomes</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> MACEs</td>
<td>43 (12.7%)</td>
<td>6 (5.3%)</td>
<td>14 (12.4%)</td>
<td>23 (20.5%)</td>
<td>
<italic>.003</italic>
</td>
</tr>
<tr>
<td> Acute myocardial infarction</td>
<td>30 (8.9%)</td>
<td>4 (3.5%)</td>
<td>10 (8.8%)</td>
<td>16 (14.3%)</td>
<td>
<italic>.018</italic>
</td>
</tr>
<tr>
<td> Coronary angioplasty</td>
<td>29 (8.6%)</td>
<td>4 (3.5%)</td>
<td>10 (8.8%)</td>
<td>15 (13.4%)</td>
<td>
<italic>.031</italic>
</td>
</tr>
<tr>
<td> Coronary bypass surgery</td>
<td>9 (2.7%)</td>
<td>1 (0.9%)</td>
<td>4 (3.5%)</td>
<td>4 (3.6%)</td>
<td>.374</td>
</tr>
<tr>
<td> All-cause mortality</td>
<td>5 (1.5%)</td>
<td>2 (1.8%)</td>
<td>1 (0.9%)</td>
<td>2 (1.8%)</td>
<td>.874</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319712455216">
<p>Abbreviations: NLR, neutrophil lymphocyte ratio; MACE, major adverse cardiac event; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.</p>
</fn>
<fn id="table-fn2-0003319712455216">
<p>
<sup>a</sup> Albumin-to-creatinine ratio (ACR) &lt;30 = no albuminuria; ACR 30-300 = microalbuminuria; ACR &gt;300 = macroalbuminuria.</p>
</fn>
<fn id="table-fn2a-0003319712455216">
<p>Note: <italic>P</italic> values in italics signify statistically significant <italic>p</italic>-values (<italic>p</italic> &lt; 0.05).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The primary outcome was a 4-year MACE rate. The 4-year MACE rate in NLR &gt; 2.4, 1.6 ≤ NLR ≤ 2.4, NLR &lt; 1.6 was, respectively, 23 (20.5%) of 112, 14 (12.4%) of 113 , and 6 of (5.3%) 113 , with Pearson chi-square = 11.76 and <italic>P</italic> = .003. Individually, the 4-year rates of AMI and PCI were significantly higher in the higher NLR tertiles. The rate of AMI was 14.3%, 8.8%, and 3.5% (chi-square <italic>P</italic> = .018) and the rate of PCI was 13.4%, 8.8%, and 3.5% (chi-square <italic>P</italic> = .031) in the third, second, and first NLR tertile, respectively. These findings are illustrated in <xref ref-type="fig" rid="fig1-0003319712455216">Figure 1</xref>. Kaplan-Meier survival curves (<xref ref-type="fig" rid="fig2-0003319712455216">Figure 2</xref>) show worse survival (with MACEs as the end point) in the higher NLR tertiles (overall log rank chi-square <italic>P</italic> = .003). Log rank test compared first NLR tertile with second NLR tertile, and second NLR tertile with third NLR tertile, showing nonsignificant <italic>P</italic> = .06 and .10, respectively. However, the comparison of the first with the third NLR tertile yields a significant <italic>P</italic> = .0006. <xref ref-type="fig" rid="fig3-0003319712455216">Figure 3</xref> shows survival curves comparing the highest tertile of NLR (NLR &gt; 2.4) with the bottom 2 tertiles (NLR ≤ 2.4). Log rank test comparing the highest tertile with the bottom 2 tertiles yields (chi-square <italic>P</italic> = .002). Thus, the highest NLR tertile (NLR &gt; 2.4) had a significantly worse survival compared with the first tertile as well as the bottom 2 tertiles taken together.</p>
<fig id="fig1-0003319712455216" position="float">
<label>Figure 1.</label>
<caption>
<p>Graph showing proportion of MACEs, MI, and PCI in diabetic patients according to neutrophil–lymphocyte ratio (NLR) tertile. NLR indicates neutrophil lymphocyte ratio; MACE, major adverse cardiac event; MI, acute myocardial infarction; PCI, percutaneous coronary intervention.</p>
</caption>
<graphic xlink:href="10.1177_0003319712455216-fig1.tif"/>
</fig>
<fig id="fig2-0003319712455216" position="float">
<label>Figure 2.</label>
<caption>
<p>Survival curves showing survival of 338 diabetic patients (with MACEs as end point) by 3 NLR tertiles. NLR indicates neutrophil–lymphocyte ratio; MACE, major adverse cardiac event.</p>
</caption>
<graphic xlink:href="10.1177_0003319712455216-fig2.tif"/>
</fig>
<fig id="fig3-0003319712455216" position="float">
<label>Figure 3.</label>
<caption>
<p>Survival curves showing survival of 338 diabetic patients (with MACEs as end point) by highest NLR tertile compared to bottom two tertiles. NLR indicates neutrophil–lymphocyte ratio; MACE, major adverse cardiac event.</p>
</caption>
<graphic xlink:href="10.1177_0003319712455216-fig3.tif"/>
</fig>
<p>
<xref ref-type="table" rid="table2-0003319712455216">Table 2</xref> shows the univariate cox proportional hazards models for variables associated with MACEs. The NLR tertile, age, hypertension, CAD, CHF, smoking, and low eGFR are significantly associated with MACEs in the univariate screen (<italic>P</italic> &lt; .2). The univariate HR for the third NLR tertile compared with the first tertile was 4.22 (95% CI 1.72-10.40, <italic>P</italic> = .002). <xref ref-type="table" rid="table2-0003319712455216">Table 2</xref> also shows the initial multivariate model built using the variables significantly associated with MACEs as well as other clinically significant variables. Since the variable CHF violated the constant hazard over time assumption, a variable containing the product of CHF with natural logarithm of time (ie, ln(time)) was added to the model. The initial model shows a hazard ratio (HR) of 2.72 (95% CI 1.03-7.13, <italic>P</italic> = .0043) of the third NLR tertile compared with the first tertile. The final multivariate model obtained through stepwise backward elimination contained the following variables: NLR tertile, history of CAD, CHF, and smoking (<xref ref-type="table" rid="table3-0003319712455216">Table 3</xref>). The adjusted HR of third NLR tertile compared with the first NLR tertile was 2.80 (95% CI 1.12-6.98, <italic>P</italic> = .027). Comparing the third NLR tertile with the bottom 2 tertiles that is NLR &gt; 2.4 versus NLR ≤ 2.4, the unadjusted HR was 2.48 (95% CI 1.36-4.52, <italic>P</italic> = .003) and the adjusted HR in a multivariate cox proportional hazard model was 2.43 (95% CI 1.33-4.45, <italic>P</italic> = .004). The variable NLR was converted with a normal distribution by natural logarithmic transformation, and considering it as a continuous variable, the unadjusted HR for absolute NLR value (log) was 2.40 (1.33-4.34, <italic>P</italic> = .004) and the adjusted HR was 2.16 (1.15-4.09, <italic>P</italic> = .017). Thus, NLR remained a significant predictor of MACEs after adjusting for several confounding factors.</p>
<table-wrap id="table2-0003319712455216" position="float">
<label>Table 2.</label>
<caption>
<p>Univariate and Initial Multivariate Cox Proportional Hazards Model for Predictors of MACE in Diabetic Patients.</p>
</caption>
<graphic alternate-form-of="table2-0003319712455216" xlink:href="10.1177_0003319712455216-table2.tif"/>
<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate HR</th>
<th>95% CI</th>
<th>
<italic>P</italic>
</th>
<th>Multivariate HR</th>
<th>95% CI</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLR tertiles</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> First NLR tertile</td>
<td>1.00 (ref)</td>
<td>
</td>
<td>
</td>
<td>1.00 (ref)</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Second tertile (NLR = 1.6-2.4)</td>
<td>2.43</td>
<td>0.93-6.32</td>
<td>
<bold>
<italic>.069</italic>
</bold>
</td>
<td>1.16</td>
<td>0.42-3.24</td>
<td>.776</td>
</tr>
<tr>
<td> Third tertile (NLR &gt; 2.4)</td>
<td>4.22</td>
<td>1.72-10.4</td>
<td>
<bold>
<italic>.002</italic>
</bold>
</td>
<td>
<bold>2.72</bold>
</td>
<td>
<bold>1.03-7.13</bold>
</td>
<td>
<bold>
<italic>.043</italic>
</bold>
</td>
</tr>
<tr>
<td>Age (per year)</td>
<td>1.04</td>
<td>1.01-1.07</td>
<td>
<bold>
<italic>.009</italic>
</bold>
</td>
<td>1.02</td>
<td>0.98-1.05</td>
<td>.306</td>
</tr>
<tr>
<td>Sex</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Male</td>
<td>1.00 (ref)</td>
<td>
</td>
<td align="center">--</td>
<td>1.00 (ref)</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Female</td>
<td>0.68</td>
<td>0.37-1.25</td>
<td>.22</td>
<td>0.87</td>
<td>0.46-1.66</td>
<td>.676</td>
</tr>
<tr>
<td>Race</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> White</td>
<td>1.00 (ref)</td>
<td>
</td>
<td align="center">--</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Black</td>
<td>0.34</td>
<td>0.10-1.13</td>
<td>.079</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Hispanic</td>
<td>0.74</td>
<td>0.31-1.75</td>
<td>.49</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Other</td>
<td>1.12</td>
<td>0.56-2.23</td>
<td>.56</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.89 </td>
<td>0.80-4.48</td>
<td>
<bold>
<italic>.15</italic>
</bold>
</td>
<td>1.36</td>
<td>0.56-3.34</td>
<td>.495</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>8.70</td>
<td>4.59-16.5</td>
<td>
<bold>
<italic>&lt;.001</italic>
</bold>
</td>
<td>
<bold>7.13</bold>
</td>
<td>
<bold>3.52-14.4</bold>
</td>
<td>
<bold>
<italic>&lt;.001</italic>
</bold>
</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>4.10</td>
<td>1.90-8.85</td>
<td>
<bold>
<italic>&lt;.001</italic>
</bold>
</td>
<td>6.22<sup>a</sup>
</td>
<td>1.44-26.8</td>
<td>
<bold>
<italic>.014</italic>
</bold>
</td>
</tr>
<tr>
<td>Cerebrovascular event</td>
<td>0.48</td>
<td>0.07-3.52</td>
<td>.47</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Smoking</td>
<td>1.53</td>
<td>0.82-2.84</td>
<td>
<bold>
<italic>.178</italic>
</bold>
</td>
<td>
<bold>2.04</bold>
</td>
<td>
<bold>1.05-3.99</bold>
</td>
<td>
<bold>
<italic>.036</italic>
</bold>
</td>
</tr>
<tr>
<td>Neuropathy</td>
<td>1.39</td>
<td>0.72-2.67</td>
<td>.32</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Retinopathy</td>
<td>0.88</td>
<td>0.31-2.47</td>
<td>.81</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Diabetic foot ulcer</td>
<td>1.15</td>
<td>0.51-2.59</td>
<td>.73</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Good glycemic control<sup>b</sup>
</td>
<td>0.62</td>
<td>0.29-1.34</td>
<td>.22</td>
<td>0.77</td>
<td>0.35-1.71</td>
<td>.52</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>1.54</td>
<td>0.68-3.46</td>
<td>.297</td>
<td>1.45</td>
<td>0.63-3.36</td>
<td>.381</td>
</tr>
<tr>
<td>Obesity</td>
<td>0.85</td>
<td>0.46-1.56</td>
<td>.595</td>
<td>0.92</td>
<td>0.49-1.74</td>
<td>.803</td>
</tr>
<tr>
<td>Albuminuria<sup>c</sup>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> None (ref)</td>
<td>1.00</td>
<td>
</td>
<td align="center">--</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Microalbuminuria</td>
<td>1.03</td>
<td>0.49-2.14</td>
<td>.937</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Macroalbuminuria</td>
<td>1.45</td>
<td>0.59-3.53</td>
<td>.414</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Low eGFR</td>
<td>1.97</td>
<td>
</td>
<td>
<bold>
<italic>.034</italic>
</bold>
</td>
<td>0.98</td>
<td>0.49-1.98</td>
<td>.96</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0003319712455216">
<p>Abbreviations: eGFR, estimated glomerular filtration rate; NLR, neutrophil lymphocyte ratio; MAC, major adverse cardiac events.</p>
</fn>
<fn id="table-fn4-0003319712455216">
<p>
<sup>a</sup> Hazard ratio obtained after incorporating product of CHF and ln(time) in the model.</p>
</fn>
<fn id="table-fn5-0003319712455216">
<p>
<sup>b</sup> Good glycemic control = HbA<sub>1</sub>c <underline>≤</underline>6.5%.</p>
</fn>
<fn id="table-fn6-0003319712455216">
<p>
<sup>c</sup> Albumin-to-creatinine ratio (ACR) &lt;30 = no albuminuria; ACR 30-300 = microalbuminuria; ACR &gt;300 = macroalbuminuria.</p>
</fn>
<fn id="table-fn6a-0003319712455216">
<p>Note: <italic>P</italic> values in italics and boldface in the third column signify <italic>p</italic> &lt; 0.2 in the univariate models. All variables with <italic>p</italic> &lt; 0.2 in the univariate models are included in the multivariate model. <italic>P</italic> values in italics and boldface in the sixth column signify statistically significant multivariate <italic>p</italic>-values (<italic>p</italic> &lt; 0.05).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0003319712455216" position="float">
<label>Table 3.</label>
<caption>
<p>Final Multivariate Cox Proportional Hazards Model Showing Independent Predictors of MACEs.</p>
</caption>
<graphic alternate-form-of="table3-0003319712455216" xlink:href="10.1177_0003319712455216-table3.tif"/>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Adjusted HR</th>
<th>95% CI</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLR tertile (third vs first)</td>
<td>2.80</td>
<td>1.12-6.98</td>
<td>.027</td>
</tr>
<tr>
<td>NLR tertile (third vs first and second)</td>
<td>2.41</td>
<td>1.32-4.42</td>
<td>.004</td>
</tr>
<tr>
<td>Absolute NLR tertile (log)</td>
<td>2.16</td>
<td>1.15-4.09</td>
<td>.017</td>
</tr>
<tr>
<td>History of coronary artery disease</td>
<td>8.12</td>
<td>4.15-15.87</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>History of congestive heart failure</td>
<td>7.36</td>
<td>1.75-31.00</td>
<td>.007</td>
</tr>
<tr>
<td>History of smoking</td>
<td>2.00</td>
<td>1.07-3.77</td>
<td>.031</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0003319712455216">
<p>Abbreviations: NLR = neutrophil lymphocyte ratio, MACE = major adverse cardiac event; HR, hazard ratio.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In order to evaluate the effect of NLR on diabetic patients without any prior history of CAD, we conducted a subgroup analysis including only the non-CAD patients (n = 261). There were 2.9% (3 of 102), 5.3% (4 of 76), and 8.4% (7 of 83) MACEs in the first, second, and third NLR tertiles, respectively (Fischer exact <italic>P</italic> = .237). Univariate Cox regression model showed a HR for absolute NLR value (log) of 2.42 (0.88-6.67, <italic>P</italic> = .086). Despite the <italic>P</italic> value in this subgroup being nonsignificant, we still see a trend of increasing MACE rates with an increase in the NLR value.</p>
<p>In order to evaluate the impact of platelet count and eosinophil count in predicting MACEs, we calculated the number of events in platelet and eosinophil count tertiles. The number of MACEs in the first (&lt;223 000/μL), second (223 000-286 000/μL), and third (&gt;286 000/μL) platelet tertiles were, respectively, 16 of 112 (14.3%), 9 of 113 (8%), and 18 of 111 (16.2%), <italic>P</italic> = .15 (<xref ref-type="fig" rid="fig4-0003319712455216">Figure 4</xref>). Similarly, the number of MACEs in first (≤0.1 × 10<sup>3</sup>/μL), second (&gt;0.1-0.2 × 10<sup>3</sup>/μL), and third (&gt;0.2 × 10<sup>3</sup>/μL) eosinophil tertiles was 0 (0.0%) of 27, 10 (11.9%) of 84, 10 (12.3%) of 81, respectively, <italic>P</italic> = .98. Of note, the MACE rate was 0 of 27 in the lowest eosinophil group (eosinophil &lt;0.1 k/cc) and the MACE rate was 23 (16%) of 144 in the group of patients with eosinophil ≥1 k/cc (<xref ref-type="fig" rid="fig5-0003319712455216">Figure 5</xref>).</p>
<fig id="fig4-0003319712455216" position="float">
<label>Figure 4.</label>
<caption>
<p>Graph showing proportion of major adverse cardiac events (MACEs) in diabetic patients according to peripheral blood platelet count (k/cc).</p>
</caption>
<graphic xlink:href="10.1177_0003319712455216-fig4.tif"/>
</fig>
<fig id="fig5-0003319712455216" position="float">
<label>Figure 5.</label>
<caption>
<p>Graph showing proportion of major adverse cardiac events (MACEs) in diabetic patients according to peripheral blood eosinophil count (k/cc).</p>
</caption>
<graphic xlink:href="10.1177_0003319712455216-fig5.tif"/>
</fig>
<p>A univariate screen for other hemogram parameters (using tertiles) showed that platelet count, total WBC count, absolute eosinophil count, and the absolute neutrophil count were not associated with MACEs, whereas the absolute lymphocyte count was associated with MACEs (HR of third vs first tertile = 0.35, <italic>P</italic> = .015; <xref ref-type="table" rid="table4-0003319712455216">Table 4</xref>). However, in multivariate models (using the same confounding variables), none of these leucocyte parameters were significant predictors of MACEs. Thus, the predictive ability of NLR is independent of the total WBC or absolute neutrophil or lymphocyte counts.</p>
<table-wrap id="table4-0003319712455216" position="float">
<label>Table 4.</label>
<caption>
<p>Univariate and Multivariate Hazard Ratios for Cox Proportional Models Predicting MACEs Using Different Hemogram Parameters.</p>
</caption>
<graphic alternate-form-of="table4-0003319712455216" xlink:href="10.1177_0003319712455216-table4.tif"/>
<table>
<thead>
<tr>
<th>Leucocyte Parameter</th>
<th>Univariate HR</th>
<th>95% CI</th>
<th>
<italic>P</italic>
</th>
<th>Multivariate HR</th>
<th>95% CI</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLR tertile (third vs first)</td>
<td>4.22</td>
<td>1.72-10.4</td>
<td>
<bold>
<italic>.002</italic>
</bold>
</td>
<td>
<bold>2.80</bold>
</td>
<td>
<bold>1.12-6.98</bold>
</td>
<td>
<bold>
<italic>.027</italic>
</bold>
</td>
</tr>
<tr>
<td>Total WBC count tertile (third vs first) </td>
<td>0.88</td>
<td>0.46-1.70</td>
<td>.707</td>
<td>0.88</td>
<td>0.45-1.72</td>
<td>.715</td>
</tr>
<tr>
<td>Absolute neutrophil count tertile (third vs first)</td>
<td>1.37</td>
<td>0.69-2.72</td>
<td>.363</td>
<td>1.19</td>
<td>0.59-2.39</td>
<td>.621</td>
</tr>
<tr>
<td>Absolute lymphocyte count tertile (third vs first)</td>
<td>0.35</td>
<td>0.15-0.82</td>
<td>
<bold>
<italic>.015</italic>
</bold>
</td>
<td>0.48</td>
<td>0.20-1.15</td>
<td>.101</td>
</tr>
<tr>
<td>Platelet count tertile (third vs first)</td>
<td>1.14</td>
<td>0.58-2.23</td>
<td>.711</td>
<td>1.37</td>
<td>0.91-2.7</td>
<td>.369</td>
</tr>
<tr>
<td>Eosinophil count (third vs first)</td>
<td>0.94</td>
<td>0.45-1.98</td>
<td>.875</td>
<td>0.75</td>
<td>0.35-1.63</td>
<td>.477</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0003319712455216">
<p>Abbreviations: NLR, neutrophil lymphocyte ratio; WBC, white blood cell; MACE, major adverse cardiovascular event.</p>
</fn>
<fn id="table-fn8a-0003319712455216">
<p>Note: <italic>P</italic> values in italics and boldface signify statistically significant <italic>p</italic>-values (<italic>p</italic> &lt; 0.05).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-0003319712455216">
<title>Discussion</title>
<sec id="section5-0003319712455216">
<title>Main Finding</title>
<p>Our study shows that NLR in diabetic patients is a predictor of MACEs. This association remains robust after adjusting for confounding factors like age, sex, hypertension, CHF, CAD, smoking, glycemic control, hyperlipidemia, and obesity. Previous studies have shown the predictive value of NLR in patients with ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) patients, post-PCI patients, and patients with chronic stable angina or CAD.<sup>
<xref ref-type="bibr" rid="bibr9-0003319712455216">9</xref>
<xref ref-type="bibr" rid="bibr10-0003319712455216"/>
<xref ref-type="bibr" rid="bibr11-0003319712455216"/>
<xref ref-type="bibr" rid="bibr12-0003319712455216"/>
<xref ref-type="bibr" rid="bibr13-0003319712455216"/>–<xref ref-type="bibr" rid="bibr14-0003319712455216">14</xref>
</sup> However, most of these studies focused on all-cause mortality, with only 1 study in patients with CAD focusing on cardiac mortality. Only 23% of patients in our diabetic population had stable CAD at the study onset. Moreover, we focused not only on cardiac-specific mortality but also on other end points like occurrence of an AMI, PCI, or CABG. The MACE is a more robust and accurate measure of CVD compared with all-cause mortality. Our study shows that those in the third NLR tertile (NLR &gt; 2.4) were 2.8 times more likely to have a major cardiovascular event over a 4-year period compared to those in the first NLR tertile (NLR &lt; 1.6) and 2.5 times more likely to have a major cardiovascular event over a 4-year period compared to those in the bottom 2 tertiles (NLR ≤ 2.4). Surprisingly, in our study population, albuminuria was not a significant predictor of the 4-year MACE rate. To our knowledge, this is the first study showing the predictive value of NLR for MACEs in diabetic patients, consisting of a predominantly non-CAD population. Despite the HR of NLR in the non-CAD subgroup (n = 261) being nonsignificant (HR = 2.42, 95% CI 0.88-6.67, <italic>P</italic> = .086), it showed a trend of increased risk of MACEs with higher NLR values. Due to the lower number of MACEs (n = 14) in this subgroup, we lacked sufficient power to detect a significant difference. Moreover, the overall multivariate cox proportional hazard model for all patients (n = 338) showed that the effect of NLR was independent of history of prior CAD.</p>
</sec>
<sec id="section6-0003319712455216">
<title>Cardiovascular Events and Neutrophils</title>
<p>After the recognition of atherosclerosis as an inflammatory process, interest in the role of immunity and immune system has grown. Elevated total WBC count has been shown to be associated with increased mortality and worse outcomes after AMI<sup>
<xref ref-type="bibr" rid="bibr15-0003319712455216">15</xref>
<xref ref-type="bibr" rid="bibr16-0003319712455216"/>–<xref ref-type="bibr" rid="bibr17-0003319712455216">17</xref>
</sup> as well as in patients with CAD.<sup>
<xref ref-type="bibr" rid="bibr18-0003319712455216">18</xref>
</sup> Studies have subsequently focused on the effect of the differential leucocyte count on outcomes in patients with atherosclerotic CVD. Elevated neutrophil count has been shown to be associated with higher MACEs in STEMI<sup>
<xref ref-type="bibr" rid="bibr19-0003319712455216">19</xref>
</sup> and peripheral artery disease patients.<sup>
<xref ref-type="bibr" rid="bibr20-0003319712455216">20</xref>
</sup> Particularly in patients with STEMI, higher neutrophil counts were a marker of larger infarctions.<sup>
<xref ref-type="bibr" rid="bibr19-0003319712455216">19</xref>
</sup> The role of neutrophils in atherosclerosis has been described in several studies, with recent studies suggesting continuous recruitment of neutrophils at various stages of atherosclerosis, from initiation to plaque rupture.<sup>
<xref ref-type="bibr" rid="bibr21-0003319712455216">21</xref>
<xref ref-type="bibr" rid="bibr22-0003319712455216"/>
<xref ref-type="bibr" rid="bibr23-0003319712455216"/>–<xref ref-type="bibr" rid="bibr24-0003319712455216">24</xref>
</sup> Hypercholesterolemia causes neutrophilia via enhanced granulopoiesis, mobilization from the bone marrow, and decreased clearance.<sup>
<xref ref-type="bibr" rid="bibr21-0003319712455216">21</xref>
</sup> Moreover, increased expression of adhesion molecules like selectin and integrin driven by cholesterol deposition in the vessel walls, in conjunction with several cytokines and chemokines, causes increased neutrophil recruitment to the endothelium.<sup>
<xref ref-type="bibr" rid="bibr25-0003319712455216">25</xref>
</sup> After migration into vessel walls, neutrophils exert their proinflammatory and atherogenic effect by interaction with other cell types like platelets, monocytes, and macrophages.<sup>
<xref ref-type="bibr" rid="bibr25-0003319712455216">25</xref>
</sup> The high inflammatory activity produced by these interactions may make the atherosclerotic plaques unstable and prone to rupture, leading to an acute event.</p>
</sec>
<sec id="section7-0003319712455216">
<title>Cardiovascular Disease Events and Lymphocytes</title>
<p>Studies have shown that low lymphocyte count is associated with higher mortality and adverse CVD outcomes in patients with chest pain, stable CAD,<sup>
<xref ref-type="bibr" rid="bibr26-0003319712455216">26</xref>
</sup> unstable angina,<sup>
<xref ref-type="bibr" rid="bibr27-0003319712455216">27</xref>
</sup> and CHF.<sup>
<xref ref-type="bibr" rid="bibr28-0003319712455216">28</xref>
</sup> The mechanism behind low lymphocyte count and adverse outcomes remains speculative, with lower lymphocyte counts representing higher level of physiologic stress secondary to cortisol release<sup>
<xref ref-type="bibr" rid="bibr29-0003319712455216">29</xref>
</sup> (after an acute event like AMI) and thereby a dysregulated inflammatory response. T-lymphocytes are unique in the sense that they are comprised of several subsets of cells some of which enhance and some of which control inflammatory and immune responses.<sup>
<xref ref-type="bibr" rid="bibr30-0003319712455216">30</xref>,<xref ref-type="bibr" rid="bibr31-0003319712455216">31</xref>
</sup>
</p>
<p>Regulatory T-cell subset of T-lymphocytes (including CD4+CD25+ T cells) has been shown in experimental mouse models to play an inhibitory role in atherosclerosis.<sup>
<xref ref-type="bibr" rid="bibr32-0003319712455216">32</xref>,<xref ref-type="bibr" rid="bibr33-0003319712455216">33</xref>
</sup> Regulatory T cells result in the upregulation of interleukin 10 (IL-10; an inhibitory cytokine) and transforming growth factor beta (TGF-β), which in turn leads to a reduction in atherosclerotic plaque accumulation.<sup>
<xref ref-type="bibr" rid="bibr34-0003319712455216">34</xref>
<xref ref-type="bibr" rid="bibr35-0003319712455216"/>–<xref ref-type="bibr" rid="bibr36-0003319712455216">36</xref>
</sup> They may also result in potential transition from T helper 1 (TH<sub>1</sub>) to T helper 2 (TH<sub>2</sub>) responses, thus favoring a B-cell response and inhibiting a proatherogenic TH<sub>1</sub> immune response.<sup>
<xref ref-type="bibr" rid="bibr32-0003319712455216">32</xref>,<xref ref-type="bibr" rid="bibr37-0003319712455216">37</xref>
</sup> B-cell response has been shown to be atheroprotective in several experimental studies.<sup>
<xref ref-type="bibr" rid="bibr38-0003319712455216">38</xref>
</sup> Additionally, human studies have shown increased TH<sub>1</sub> subsets in patients with advanced atherosclerosis and unstable angina, with elevated interferon-γ (IFN-γ) and reduced TGF-β and IL-10 levels in the plasma of these patients, further suggesting decreased regulatory T-cell activity.<sup>
<xref ref-type="bibr" rid="bibr39-0003319712455216">39</xref>
<xref ref-type="bibr" rid="bibr40-0003319712455216"/>
<xref ref-type="bibr" rid="bibr41-0003319712455216"/>–<xref ref-type="bibr" rid="bibr42-0003319712455216">42</xref>
</sup> Studies have also shown direct evidence of decreased level and activity of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes.<sup>
<xref ref-type="bibr" rid="bibr43-0003319712455216">43</xref>,<xref ref-type="bibr" rid="bibr44-0003319712455216">44</xref>
</sup> Another study in mice showed reduced number of circulating immunoregulatory CD31+ T cells as the hallmark of plaque thrombosis.<sup>
<xref ref-type="bibr" rid="bibr45-0003319712455216">45</xref>
</sup> Subsequent replacement therapy with CD31 globulin resulted in improvement in experimental atherosclerosis.<sup>
<xref ref-type="bibr" rid="bibr46-0003319712455216">46</xref>
</sup> CD31+ T cells represent &lt;20% of human peripheral blood lymphocytes, decrease with age, and have been shown in vitro to regulate T-cell activation.<sup>
<xref ref-type="bibr" rid="bibr45-0003319712455216">45</xref>
</sup> We hypothesize that low total lymphocyte count represents low regulatory T-cell activity, and higher lymphocyte count represents more regulatory T-cell activity and a stable, quiescent inflammatory response. However, this link between total lymphocyte count and regulatory T-cell activity remains speculative and needs to be elucidated in future experimental and laboratory studies.</p>
</sec>
<sec id="section8-0003319712455216">
<title>Effect of Smoking</title>
<p>It has been reported that participants who ever smoked tend to have a higher total WBC count compared with those who never smoked.<sup>
<xref ref-type="bibr" rid="bibr47-0003319712455216">47</xref>,<xref ref-type="bibr" rid="bibr48-0003319712455216">48</xref>
</sup> In our study, the mean WBC in smokers (current or past) and nonsmokers, respectively, was 7.94 × 10<sup>3</sup>/μL and 7.00 × 10<sup>3</sup>/μL (<italic>P</italic> &lt; .001). The relationship between smoking and NLR is controversial. It has been proposed that obese participants who smoke may have a falsely low value of NLR due to the systemic inflammatory state in these participants causing migration of neutrophils to peripheral tissues. Some studies reported a lower NLR in smokers,<sup>
<xref ref-type="bibr" rid="bibr10-0003319712455216">10</xref>,<xref ref-type="bibr" rid="bibr49-0003319712455216">49</xref>,<xref ref-type="bibr" rid="bibr11-0003319712455216">11</xref>
</sup> whereas Papa et al<sup>
<xref ref-type="bibr" rid="bibr14-0003319712455216">14</xref>
</sup> reported no difference. In our study, there is no significant difference in NLR value of smokers compared with nonsmokers (<xref ref-type="table" rid="table1-0003319712455216">Table 1</xref>). Given the relationship between smoking and WBC count, we conducted a stratified analysis to avoid any confounding effect of smoking, which showed an increase in MACEs with higher NLR tertiles in both smokers and nonsmokers (<xref ref-type="fig" rid="fig6-0003319712455216">Figure 6</xref>).</p>
<fig id="fig6-0003319712455216" position="float">
<label>Figure 6.</label>
<caption>
<p>The 4-year major adverse cardiac event (MACE) according to the baseline 2007 neutrophil–lymphocyte ratio (NLR) and the smoking status. Smokers include both active and ex-smokers. <italic>P</italic> = .049 for third versus first NLR tertiles among nonsmokers, <italic>P</italic> = .021 for third versus first NLR tertiles among smokers. NLR indicates neutrophil–lymphocyte ratio.</p>
</caption>
<graphic xlink:href="10.1177_0003319712455216-fig6.tif"/>
</fig>
</sec>
<sec id="section9-0003319712455216">
<title>Platelet and Eosinophil Counts</title>
<p>Avramakis et al<sup>
<xref ref-type="bibr" rid="bibr50-0003319712455216">50</xref>
</sup> in their study showed that patients with an acute coronary syndrome (unstable angina or myocardial infarction) tended to have lower platelet counts, higher Mean Platelet Volume (MPV), and lower eosinophil counts, thereby reflecting consumption at the site of the coronary artery thrombosis. It was proposed that both platelets and eosinophils have procoagulant properties which contribute to the occurrence of acute coronary event. In our study, however, there was no significant correlation between higher platelet and eosinophil tertiles and occurrence of MACEs (<xref ref-type="fig" rid="fig4-0003319712455216">Figures 4</xref> and <xref ref-type="fig" rid="fig5-0003319712455216">5</xref> and <xref ref-type="table" rid="table4-0003319712455216">Table 4</xref>). The only notable finding was an absence of MACEs in participants with eosinophil count &lt;0.1 (×10<sup>3</sup>/μL). However, it is noteworthy to mention that our study was based on nonacute coronary syndrome population, and the study of Avramakis et al<sup>
<xref ref-type="bibr" rid="bibr50-0003319712455216">50</xref>
</sup> was based on an acute coronary syndrome population.</p>
</sec>
<sec id="section10-0003319712455216">
<title>Superiority of NLR Over Absolute Leucocyte Counts</title>
<p>The NLR represents a ratio between the absolute neutrophil and absolute lymphocyte count, thus representing 2 inversely related immune pathways—one representing uncontrolled inflammation and the other representing a stable and quiescent inflammatory pathway. It is a more stable measure than the individual absolute cell counts and less affected by several conditions which change the individual cell counts. Previous studies have described the superiority of NLR over individual neutrophil and leucocyte counts.<sup>
<xref ref-type="bibr" rid="bibr11-0003319712455216">11</xref>,<xref ref-type="bibr" rid="bibr10-0003319712455216">10</xref>
</sup> In our study, the absolute neutrophil count was not a significant predictor of MACEs; and although the absolute lymphocyte count was a significant inverse predictor of MACEs in univariate analysis, this effect did not persist in multivariate analysis. The NLR continued to be a significant predictor of MACEs in both univariate and multivariate analyses.</p>
</sec>
<sec id="section11-0003319712455216">
<title>Neutrophils, Lymphocytes, and NLR in Diabetic Patients</title>
<p>Diabetic patients tend to have a higher total and differential leucocyte count compared with normal controls. Experimental mouse models showed sustained hyperglycemia produces increased levels of adherent and emigrated leucocytes but decreased bacterial clearance due to impaired phagocytic activity.<sup>
<xref ref-type="bibr" rid="bibr51-0003319712455216">51</xref>
</sup> Another study showed increased expression of activation markers like CD11b/CD18 on monocytes and neutrophils in type 2 diabetic patients, resulting in increased neutrophil adhesiveness to the endothelium, independent of fasting glucose levels.<sup>
<xref ref-type="bibr" rid="bibr52-0003319712455216">52</xref>,<xref ref-type="bibr" rid="bibr53-0003319712455216">53</xref>
</sup> Leptin may be responsible for increased leucocyte counts in diabetic patients by stimulating myeloid differentiation from bone marrow progenitor cells.<sup>
<xref ref-type="bibr" rid="bibr54-0003319712455216">54</xref>
</sup> Leucocytes in diabetic patients may also be activated by advanced glycation end products.<sup>
<xref ref-type="bibr" rid="bibr55-0003319712455216">55</xref>
</sup> Activated leucocytes then contribute to systemic inflammation and resultant endothelial damage by release of reactive oxygen species (ROS) via neutrophils<sup>
<xref ref-type="bibr" rid="bibr56-0003319712455216">56</xref>
</sup> and release of cytokines. Proinflammatory cytokines, particularly IL-6, tumor necrosis factor alpha (TNF-α), and adiponectins, have been shown to be elevated in patients with type 2 DM<sup>
<xref ref-type="bibr" rid="bibr57-0003319712455216">57</xref>
</sup> and along with ROS, they promote atherosclerosis, endothelial dysfunction, and plaque rupture. In addition, the relative number of regulatory (ie, suppressor) T cells compared to helper T cells is reduced in patients with DM.<sup>
<xref ref-type="bibr" rid="bibr58-0003319712455216">58</xref>
</sup> People with prevalent chronic diseases like DM and hypertension tend to have a higher value of NLR, thereby reflecting its role as a marker of systemic inflammation,<sup>
<xref ref-type="bibr" rid="bibr59-0003319712455216">59</xref>
</sup> with uncontrolled neutrophil activity and decreased regulatory T-cell activity. Studies have shown association between leucocyte counts including total and differential counts and macrovascular complications in type 2 DM.<sup>
<xref ref-type="bibr" rid="bibr60-0003319712455216">60</xref>
<xref ref-type="bibr" rid="bibr61-0003319712455216"/>–<xref ref-type="bibr" rid="bibr62-0003319712455216">62</xref>
</sup> One study showed increased clustering of NLR with metabolic syndrome and ischemic CVDs in type 2 DM.<sup>
<xref ref-type="bibr" rid="bibr61-0003319712455216">61</xref>
</sup> However, this was a prevalence study looking at a single cross section of time compared with our study which showed increasing <italic>incidence</italic> of MACEs with higher NLR tertiles over a 4-year period. Leucocyte differential has also been shown to be associated with components of metabolic syndrome in type 2 DM patients,<sup>
<xref ref-type="bibr" rid="bibr61-0003319712455216">61</xref>,<xref ref-type="bibr" rid="bibr63-0003319712455216">63</xref>,<xref ref-type="bibr" rid="bibr64-0003319712455216">64</xref>
</sup> which in itself is an independent risk factor for CVD. We propose that the aforementioned effects of inflammation on atherosclerosis (reflected by higher NLR values) as well as the higher prevalence of metabolic syndrome with higher NLR values explains the association of NLR with adverse cardiovascular events in our population of type 2 diabetic patients. Whether high NLR (NLR &gt; 2.4) in type 2 diabetic patients is simply a prognostic marker of CVD or plays a causal role in its pathogenesis remains a point of debate and needs to be elucidated with further observational and experimental data.</p>
</sec>
<sec id="section12-0003319712455216">
<title>Study Limitations</title>
<p>Limitations of our study include the relatively small sample size, limited ethnic diversity, and a single-center study, thus limiting generalizability. Moreover, using tertiles for NLR make the absolute number of NLR associated with adverse outcomes (NLR &gt; 2.4) difficult to reproduce in other populations (which may have a different range of NLR). Our findings need to be validated by further studies in different population subgroups. However, we used MACEs rather than overall mortality as the CVD end point, and our study is the first to demonstrate an association between NLR and MACEs.</p>
</sec>
</sec>
<sec id="section13-0003319712455216">
<title>Conclusions</title>
<p>Elevated NLR as an inflammatory marker was a significant independent predictor of MACEs in diabetic patients. The NLR was superior to other leukocyte parameters. Surprisingly, in our study population, NLR and not albuminuria was found to be a significant predictor of MACEs. Simultaneous measurement of other inflammatory markers and cytokines can further establish the proposed mechanism of our finding. Further studies with a larger number and/or a longer follow-up period are needed.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>The authors would like to acknowledge the many valuable suggestions and the critical review made by Prof Dr Dimitri P. Mikhailidis.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319712455216">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319712455216">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319712455216">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Global healthcare expenditure on diabetes for 2010 and 2030</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2010</year>;<volume>87</volume>(<issue>3</issue>):<fpage>293</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr2-0003319712455216">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>GL</given-names>
</name>
<etal/>
</person-group>. <article-title>Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>100</volume>(<issue>10</issue>):<fpage>1134</fpage>–<lpage>1146</lpage>.</citation>
</ref>
<ref id="bibr3-0003319712455216">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stamler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vaccaro</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Neaton</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Wentworth</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial</article-title>. <source>Diabetes Care</source>. <year>1993</year>;<volume>16</volume>(<issue>2</issue>):<fpage>434</fpage>–<lpage>444</lpage>.</citation>
</ref>
<ref id="bibr4-0003319712455216">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kannel</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>McGee</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Diabetes and cardiovascular risk factors: the Framingham study</article-title>. <source>Circulation</source>. <year>1979</year>;<volume>59</volume>(<issue>1</issue>):<fpage>8</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr5-0003319712455216">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caprio</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Alberti</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>King</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Cardiovascular complications of diabetes</article-title>. <source>Diabetologia</source>. <year>1997</year>;<volume>40</volume>(<issue>suppl 3</issue>):<fpage>B78</fpage>–<lpage>B82</lpage>.</citation>
</ref>
<ref id="bibr6-0003319712455216">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Libby</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Maseri</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Inflammation and atherosclerosis</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>105</volume>(<issue>9</issue>):<fpage>1135</fpage>–<lpage>1143</lpage>.</citation>
</ref>
<ref id="bibr7-0003319712455216">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Wautier</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis</article-title>. <source>Circ Res</source>. <year>1999</year>;<volume>84</volume>(<issue>5</issue>):<fpage>489</fpage>–<lpage>497</lpage>.</citation>
</ref>
<ref id="bibr8-0003319712455216">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baynes</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Thorpe</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Role of oxidative stress in diabetic complications: a new perspective on an old paradigm</article-title>. <source>Diabetes</source>. <year>1999</year>;<volume>48</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr9-0003319712455216">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Value of early risk stratification using hemoglobin level and neutrophil-to-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention</article-title>. <source>Am J Cardiol</source>. <year>2011</year>;<volume>107</volume>(<issue>6</issue>):<fpage>849</fpage>–<lpage>856</lpage>.</citation>
</ref>
<ref id="bibr10-0003319712455216">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nunez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nunez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bodi</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction</article-title>. <source>Am J Cardiol</source>. <year>2008</year>;<volume>101</volume>(<issue>6</issue>):<fpage>747</fpage>–<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr11-0003319712455216">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azab</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zaher</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weiserbs</surname>
<given-names>KF</given-names>
</name>
<etal/>
</person-group>. <article-title>Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction</article-title>. <source>Am J Cardiol</source>. <year>2010</year>;<volume>106</volume>(<issue>4</issue>):<fpage>470</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr12-0003319712455216">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamhane</surname>
<given-names>UU</given-names>
</name>
<name>
<surname>Aneja</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Eagle</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Gurm</surname>
<given-names>HS</given-names>
</name>
</person-group>. <article-title>Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome</article-title>. <source>Am J Cardiol</source>. <year>2008</year>;<volume>102</volume>(<issue>6</issue>):<fpage>653</fpage>–<lpage>657</lpage>.</citation>
</ref>
<ref id="bibr13-0003319712455216">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duffy</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Gurm</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Rajagopal</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention</article-title>. <source>Am J Cardiol</source>. <year>2006</year>;<volume>97</volume>(<issue>7</issue>):<fpage>993</fpage>–<lpage>996</lpage>.</citation>
</ref>
<ref id="bibr14-0003319712455216">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Emdin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passino</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Michelassi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cocci</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease</article-title>. <source>Clin Chim Acta</source>. <year>2008</year>;<volume>395</volume>(<issue>1-2</issue>):<fpage>27</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr15-0003319712455216">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prasad</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Stuckey</surname>
<given-names>TD</given-names>
</name>
<etal/>
</person-group>. <article-title>Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>99</volume>(<issue>8</issue>):<fpage>1067</fpage>–<lpage>1071</lpage>.</citation>
</ref>
<ref id="bibr16-0003319712455216">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Jim</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Siu</surname>
<given-names>CW</given-names>
</name>
<etal/>
</person-group>. <article-title>Leukocytosis and clinical outcomes in acute inferior myocardial infarction</article-title>. <source>Int J Cardiol</source>. <year>2007</year>;<volume>118</volume>(<issue>2</issue>):<fpage>278</fpage>–<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr17-0003319712455216">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menon</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lessard</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yarzebski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Furman</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Gore</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Leukocytosis and adverse hospital outcomes after acute myocardial infarction</article-title>. <source>Am J Cardiol</source>. <year>2003</year>;<volume>92</volume>(<issue>4</issue>):<fpage>368</fpage>–<lpage>372</lpage>.</citation>
</ref>
<ref id="bibr18-0003319712455216">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Croft</surname>
<given-names>JB</given-names>
</name>
</person-group>. <article-title>White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort</article-title>. <source>J Clin Epidemiol</source>. <year>2001</year>;<volume>54</volume>(<issue>3</issue>):<fpage>316</fpage>–<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr19-0003319712455216">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Husser</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Bodi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sanchis</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>White blood cell subtypes after STEMI: temporal evolution, association with cardiovascular magnetic resonance–derived infarct size and impact on outcome</article-title>. <source>Inflammation</source>. <year>2011</year>;<volume>34</volume>(<issue>2</issue>):<fpage>73</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr20-0003319712455216">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haumer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Amighi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Exner</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of neutrophils and future cardiovascular events in patients with peripheral artery disease</article-title>. <source>J Vasc Surg</source>. <year>2005</year>;<volume>41</volume>(<issue>4</issue>):<fpage>610</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr21-0003319712455216">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drechsler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Megens</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>van Zandvoort</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Soehnlein</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>122</volume>(<issue>18</issue>):<fpage>1837</fpage>–<lpage>1845</lpage>.</citation>
</ref>
<ref id="bibr22-0003319712455216">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rotzius</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thams</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Soehnlein</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Distinct infiltration of neutrophils in lesion shoulders in ApoE-/- mice</article-title>. <source>Am J Pathol</source>. <year>2010</year>;<volume>177</volume>(<issue>1</issue>):<fpage>493</fpage>–<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr23-0003319712455216">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zernecke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bot</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Djalali-Talab</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis</article-title>. <source>Circ Res</source>. <year>2008</year>;<volume>102</volume>(<issue>2</issue>):<fpage>209</fpage>–<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr24-0003319712455216">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ionita</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>van den Borne</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Catanzariti</surname>
<given-names>LM</given-names>
</name>
<etal/>
</person-group>. <article-title>High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2010</year>;<volume>30</volume>(<issue>9</issue>):<fpage>1842</fpage>–<lpage>1848</lpage>.</citation>
</ref>
<ref id="bibr25-0003319712455216">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drechsler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Doring</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Megens</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Soehnlein</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Neutrophilic granulocytes - promiscuous accelerators of atherosclerosis</article-title>. <source>Thromb Haemost</source>. <year>2011</year>;<volume>106</volume>(<issue>5</issue>):<fpage>839</fpage>–<lpage>848</lpage>.</citation>
</ref>
<ref id="bibr26-0003319712455216">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ommen</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hodge</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>SP</given-names>
</name>
</person-group>. <article-title>Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease</article-title>. <source>Am J Cardiol</source>. <year>1997</year>;<volume>79</volume>(<issue>6</issue>):<fpage>812</fpage>–<lpage>814</lpage>.</citation>
</ref>
<ref id="bibr27-0003319712455216">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zouridakis</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Garcia-Moll</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Kaski</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris</article-title>. <source>Am J Cardiol</source>. <year>2000</year>;<volume>86</volume>(<issue>4</issue>):<fpage>449</fpage>–<lpage>451</lpage>.</citation>
</ref>
<ref id="bibr28-0003319712455216">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ommen</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Hodge</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Rodeheffer</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>McGregor</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Predictive power of the relative lymphocyte concentration in patients with advanced heart failure</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>97</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr29-0003319712455216">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomson</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Nugent</surname>
<given-names>CA</given-names>
</name>
</person-group>. <article-title>Endogenous cortisol: a regulator of the number of lymphocytes in peripheral blood</article-title>. <source>Clin Immunol Immunopathol</source>. <year>1980</year>;<volume>17</volume>(<issue>4</issue>):<fpage>506</fpage>–<lpage>514</lpage>.</citation>
</ref>
<ref id="bibr30-0003319712455216">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbas</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Sher</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Functional diversity of helper T lymphocytes</article-title>. <source>Nature</source>. <year>1996</year>;<volume>383</volume>(<issue>6603</issue>):<fpage>787</fpage>–<lpage>793</lpage>.</citation>
</ref>
<ref id="bibr31-0003319712455216">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantor</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>E.</given-names>
</name>
</person-group> <article-title>Regulation of the immune response by subclasses of T lymphocytes. I. Interactions between pre-killer T cells and regulatory T cells obtained from peripheral lymphoid tissues of mice</article-title>. <source>Eur J Immunol</source>. <year>1975</year>;<volume>5</volume>(<issue>5</issue>):<fpage>330</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr32-0003319712455216">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mallat</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gojova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brun</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>108</volume>(<issue>10</issue>):<fpage>1232</fpage>–<lpage>1237</lpage>.</citation>
</ref>
<ref id="bibr33-0003319712455216">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ait-Oufella</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Salomon</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Potteaux</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Natural regulatory T cells control the development of atherosclerosis in mice</article-title>. <source>Nature Med</source>. <year>2006</year>;<volume>12</volume>(<issue>2</issue>):<fpage>178</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr34-0003319712455216">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tedgui</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mallat</surname>
<given-names>Z</given-names>
</name>
</person-group>. <article-title>Cytokines in atherosclerosis: pathogenic and regulatory pathways</article-title>. <source>Physiol Rev</source>. <year>2006</year>;<volume>86</volume>(<issue>2</issue>):<fpage>515</fpage>–<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr35-0003319712455216">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mallat</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Besnard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Duriez</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Protective role of interleukin-10 in atherosclerosis</article-title>. <source>Circ Res</source>. <year>1999</year>;<volume>85</volume>(<issue>8</issue>):<fpage>e17</fpage>–<lpage>e24</lpage>.</citation>
</ref>
<ref id="bibr36-0003319712455216">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robertson</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Rudling</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gorelik</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Flavell</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Hansson</surname>
<given-names>GK</given-names>
</name>
</person-group>. <article-title>Disruption of TGF-beta signaling in T cells accelerates atherosclerosis</article-title>. <source>J Clin Invest</source>. <year>2003</year>;<volume>112</volume>(<issue>9</issue>):<fpage>1342</fpage>–<lpage>1350</lpage>.</citation>
</ref>
<ref id="bibr37-0003319712455216">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis</article-title>. <source>Nat Clin Pract Cardiovasc Med</source>. <year>2008</year>;<volume>5</volume>(<issue>9</issue>):<fpage>531</fpage>–<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr38-0003319712455216">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stoll</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bendszus</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Inflammation and atherosclerosis: novel insights into plaque formation and destabilization</article-title>. <source>Stroke</source>. <year>2006</year>;<volume>37</volume>(<issue>7</issue>):<fpage>1923</fpage>–<lpage>1932</lpage>.</citation>
</ref>
<ref id="bibr39-0003319712455216">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liuzzo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kopecky</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RL</given-names>
</name>
<etal/>
</person-group>. <article-title>Perturbation of the T-cell repertoire in patients with unstable angina</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>100</volume>(<issue>21</issue>):<fpage>2135</fpage>–<lpage>2139</lpage>.</citation>
</ref>
<ref id="bibr40-0003319712455216">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liuzzo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vallejo</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Kopecky</surname>
<given-names>SL</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular fingerprint of interferon-gamma signaling in unstable angina</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>103</volume>(<issue>11</issue>):<fpage>1509</fpage>–<lpage>1514</lpage>.</citation>
</ref>
<ref id="bibr41-0003319712455216">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grainger</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Metcalfe</surname>
<given-names>JC</given-names>
</name>
<etal/>
</person-group>. <article-title>The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis</article-title>. <source>Nat Med</source>. <year>1995</year>;<volume>1</volume>(<issue>1</issue>):<fpage>74</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr42-0003319712455216">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Irving</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Sheldon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kaski</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>(<issue>7</issue>):<fpage>746</fpage>–<lpage>749</lpage>.</citation>
</ref>
<ref id="bibr43-0003319712455216">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Luboshits</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Planer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Keren</surname>
<given-names>G</given-names>
</name>
<name>
<surname>George</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes</article-title>. <source>Eur Heart J</source>. <year>2006</year>;<volume>27</volume>(<issue>21</issue>):<fpage>2530</fpage>–<lpage>2537</lpage>.</citation>
</ref>
<ref id="bibr44-0003319712455216">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes</article-title>. <source>Clin Immunol</source>. <year>2007</year>;<volume>124</volume>(<issue>1</issue>):<fpage>90</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr45-0003319712455216">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caligiuri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Groyer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Khallou-Laschet</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Reduced immunoregulatory CD31+ T cells in the blood of atherosclerotic mice with plaque thrombosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2005</year>;<volume>25</volume>(<issue>8</issue>):<fpage>1659</fpage>–<lpage>1664</lpage>.</citation>
</ref>
<ref id="bibr46-0003319712455216">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groyer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ait-Oufella</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T-cells</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>(<issue>4</issue>):<fpage>344</fpage>–<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr47-0003319712455216">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kannel</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>PW</given-names>
</name>
</person-group>. <article-title>White blood cell count and cardiovascular disease. Insights from the Framingham Study</article-title>. <source>JAMA</source>. <year>1992</year>;<volume>267</volume>(<issue>9</issue>):<fpage>1253</fpage>–<lpage>1256</lpage>.</citation>
</ref>
<ref id="bibr48-0003319712455216">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sunyer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Munoz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Longitudinal relation between smoking and white blood cells</article-title>. <source>Am J Epidemiol</source>. <year>1996</year>;<volume>144</volume>(<issue>8</issue>):<fpage>734</fpage>–<lpage>741</lpage>.</citation>
</ref>
<ref id="bibr49-0003319712455216">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibson</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Croal</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Cuthbertson</surname>
<given-names>BH</given-names>
</name>
<etal/>
</person-group>. <article-title>Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting</article-title>. <source>Am Heart J</source>. <year>2007</year>;<volume>154</volume>(<issue>5</issue>):<fpage>995</fpage>–<lpage>1002</lpage>.</citation>
</ref>
<ref id="bibr50-0003319712455216">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avramakis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Papadimitraki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Papakonstandinou</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina</article-title>. <source>Platelets</source>. <year>2007</year>;<volume>18</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr51-0003319712455216">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersson</surname>
<given-names>US</given-names>
</name>
<name>
<surname>Christoffersson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Massena</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Increased recruitment but impaired function of leukocytes during inflammation in mouse models of type 1 and type 2 diabetes</article-title>. <source>PloS One</source>. <year>2011</year>;<volume>6</volume>(<issue>7</issue>) <fpage>e22480</fpage>.</citation>
</ref>
<ref id="bibr52-0003319712455216">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Oostrom</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>van Wijk</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Sijmonsma</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Rabelink</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Castro Cabezas</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Increased expression of activation markers on monocytes and neutrophils in type 2 diabetes</article-title>. <source>Neth J Med</source>. <year>2004</year>;<volume>62</volume>(<issue>9</issue>):<fpage>320</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr53-0003319712455216">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berliner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rogowski</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rotstein</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Activated polymorphonuclear leukocytes and monocytes in the peripheral blood of patients with ischemic heart and brain conditions correspond to the presence of multiple risk factors for atherothrombosis</article-title>. <source>Cardiology</source>. <year>2000</year>;<volume>94</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr54-0003319712455216">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YJ</given-names>
</name>
</person-group>. <article-title>Peripheral total and differential leukocyte count in diabetic nephropathy: the relationship of plasma leptin to leukocytosis</article-title>. <source>Diabetes Care</source>. <year>2005</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1710</fpage>–<lpage>1717</lpage>.</citation>
</ref>
<ref id="bibr55-0003319712455216">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pertynska-Marczewska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kiriakidis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wait</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Beech</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Feldmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Paleolog</surname>
<given-names>EM</given-names>
</name>
</person-group>. <article-title>Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages</article-title>. <source>Cytokine</source>. <year>2004</year>;<volume>28</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr56-0003319712455216">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shurtz-Swirski</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sela</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Herskovits</surname>
<given-names>AT</given-names>
</name>
<etal/>
</person-group>. <article-title>Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients</article-title>. <source>Diabetes Care</source>. <year>2001</year>;<volume>24</volume>(<issue>1</issue>):<fpage>104</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr57-0003319712455216">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirza</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hossain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mathews</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study</article-title>. <source>Cytokine</source>. <year>2012</year>;<volume>57</volume>(<issue>1</issue>):<fpage>136</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr58-0003319712455216">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fontana</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lapolla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sanzari</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>An immunological evaluation of type II diabetic patients with periodontal disease</article-title>. <source>J Diabetes Complications</source>. <year>1999</year>;<volume>13</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr59-0003319712455216">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imtiaz</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shafique</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mirza</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Ayoob</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Vart</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population</article-title>. <source>Int Arch Med</source>. <year>2012</year>;<volume>5</volume>(<issue>1</issue>):<fpage>2</fpage>.</citation>
</ref>
<ref id="bibr60-0003319712455216">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moradi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kerman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Rohani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Salari</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Association between diabetes complications and leukocyte counts in Iranian patients</article-title>. <source>J Inflam Res</source>. <year>2012</year>;<volume>5</volume>:<fpage>7</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr61-0003319712455216">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Sheu</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>HC</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2007</year>;<volume>23</volume>(<issue>2</issue>):<fpage>111</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr62-0003319712455216">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tong</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>So</surname>
<given-names>WY</given-names>
</name>
<etal/>
</person-group>. <article-title>White blood cell count is associated with macro- and microvascular complications in chinese patients with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2004</year>;<volume>27</volume>(<issue>1</issue>):<fpage>216</fpage>–<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr63-0003319712455216">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shim</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>ES</given-names>
</name>
<etal/>
</person-group>. <article-title>The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2006</year>;<volume>73</volume>(<issue>3</issue>):<fpage>284</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr64-0003319712455216">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pratley</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bogardus</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Relation of the white blood cell count to obesity and insulin resistance: effect of race and gender</article-title>. <source>Obes Res</source>. <year>1995</year>;<volume>3</volume>(<issue>6</issue>):<fpage>563</fpage>–<lpage>571</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>